» Articles » PMID: 33050194

The Functional Role of MicroRNAs in the Pathogenesis of Tauopathy

Overview
Journal Cells
Publisher MDPI
Date 2020 Oct 14
PMID 33050194
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Tauopathies are neurodegenerative disorders which include Alzheimer's disease, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy among others. Pathologically, they are characterized by the accumulation of highly phosphorylated and aggregated tau protein in different brain regions. Currently, the mechanisms responsible for their pathogenesis are not known, and for this reason, there is no cure. MicroRNAs (miRNAs) are abundantly present in the central nervous system where they act as master regulators of pathways considered important for tau post-translational modifications, metabolism, and clearance. Although in recent years, several miRNAs have been reported to be altered in tauopathy, we still do not know whether these changes contribute to the onset and progression of the disorder, or are secondary events following the development of tau neuropathology. Additionally, since miRNAs are relatively stable in biological fluids and their measurement is easy and non-invasive, these small molecules hold the potential to function as biomarkers for tauopathy. Herein, we showcase recent findings on the biological link between miRNAs and the pathogenesis of tauopathy, and present emerging evidence supporting their role as biomarkers and targets for novel therapies against them.

Citing Articles

Posterior cingulate cortex microRNA dysregulation differentiates cognitive resilience, mild cognitive impairment, and Alzheimer's disease.

Counts S, Beck J, Maloney B, Malek-Ahmadi M, Ginsberg S, Mufson E Alzheimers Dement. 2025; 21(2):e70019.

PMID: 40008917 PMC: 11863362. DOI: 10.1002/alz.70019.


Argonaute protein assisted drug discovery for miRNA-181c-5p and target gene ATM translation repression: a computational approach.

Tak H, Anirudh J, Chattopadhyay A, Naick B Mol Divers. 2024; 29(1):351-365.

PMID: 39026118 DOI: 10.1007/s11030-024-10855-3.


MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.

Azam H, Rossling R, Geithe C, Khan M, Dinter F, Hanack K Front Mol Neurosci. 2024; 17:1386735.

PMID: 38883980 PMC: 11177777. DOI: 10.3389/fnmol.2024.1386735.


Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy.

Pavelka L, Rauschenberger A, Hemedan A, Ostaszewski M, Glaab E, Kruger R Brain Commun. 2024; 6(3):fcae187.

PMID: 38863572 PMC: 11166179. DOI: 10.1093/braincomms/fcae187.


The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.

Buchholz S, Zempel H Alzheimers Dement. 2024; 20(5):3606-3628.

PMID: 38556838 PMC: 11095451. DOI: 10.1002/alz.13784.


References
1.
Smith P, Delay C, Girard J, Papon M, Planel E, Sergeant N . MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet. 2011; 20(20):4016-24. DOI: 10.1093/hmg/ddr330. View

2.
Tatura R, Buchholz M, Dickson D, Van Swieten J, McLean C, Hoglinger G . microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). Neurogenetics. 2016; 17(3):165-71. DOI: 10.1007/s10048-016-0480-6. View

3.
Geekiyanage H, Jicha G, Nelson P, Chan C . Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2011; 235(2):491-6. PMC: 3361462. DOI: 10.1016/j.expneurol.2011.11.026. View

4.
Weiss K, Antoniou A, Schratt G . Non-coding mechanisms of local mRNA translation in neuronal dendrites. Eur J Cell Biol. 2015; 94(7-9):363-7. DOI: 10.1016/j.ejcb.2015.05.011. View

5.
Moussaud S, Jones D, Moussaud-Lamodiere E, Delenclos M, Ross O, McLean P . Alpha-synuclein and tau: teammates in neurodegeneration?. Mol Neurodegener. 2014; 9:43. PMC: 4230508. DOI: 10.1186/1750-1326-9-43. View